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Abstract
MicroRNAs (miRNAs) are short (,22 nucleotides) regulatory RNAs that can modulate gene expression and are aberrantly
expressed in many diseases including cancer. Previous studies have shown that miRNAs inhibit the translation and facilitate
the degradation of their targeted messenger RNAs (mRNAs) making them attractive candidates for use in cancer therapy.
However, the potential clinical utility of miRNAs in cancer therapy rests heavily upon our ability to understand and
accurately predict the consequences of fluctuations in levels of miRNAs within the context of complex tumor cells. To
evaluate the predictive power of current models, levels of miRNAs and their targeted mRNAs were measured in laser
captured micro-dissected (LCM) ovarian cancer epithelial cells (CEPI) and compared with levels present in ovarian surface
epithelial cells (OSE). We found that the predicted inverse correlation between changes in levels of miRNAs and levels of
their mRNA targets held for only ,11% of predicted target mRNAs. We demonstrate that this low inverse correlation
between changes in levels of miRNAs and their target mRNAs in vivo is not merely an artifact of inaccurate miRNA target
predictions but the likely consequence of indirect cellular processes that modulate the regulatory effects of miRNAs in vivo.
Our findings underscore the complexities of miRNA-mediated regulation in vivo and the necessity of understanding the
basis of these complexities in cancer cells before the therapeutic potential of miRNAs can be fully realized.
Citation: Shahab SW, Matyunina LV, Mezencev R, Walker LD, Bowen NJ, et al. (2011) Evidence for the Complexity of MicroRNA-Mediated Regulation in Ovarian
Cancer: A Systems Approach. PLoS ONE 6(7): e22508. doi:10.1371/journal.pone.0022508
Editor: Moray Campbell, Roswell Park Cancer Institute, United States of America
Received March 10, 2011; Accepted June 27, 2011; Published July 21, 2011
Copyright:  2011 Shahab et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by The Ovarian Cancer Institute, The Ovarian Cycle Foundation, The Robinson Family Foundation, The Deborah Nash
Willingham Endowment Fund, The Waterfall Foundation and OBNET Women’s Healthcare. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: john.mcdonald@biology.gatech.edu
Introduction
MicroRNAs (miRNAs) are members of an abundant class of
small (,22 nts) regulatory RNAs believed to play significant roles
in a variety of biological processes and diseases in both plants and
animals [1]. Of recent interest, is the possible contribution of
aberrantly expressed miRNAs to cancer initiation and develop-
ment [2,3]. Numerous in vitro studies have demonstrated that
miRNAs are capable of inhibiting the translation and/or
facilitating the degradation [4,5,6,7] of their targeted mRNAs
making them attractive candidates for potential use in cancer
therapy [8,9]. However, the potential clinical utility of miRNAs in
cancer therapy rests heavily upon our ability to understand and
accurately predict the consequences of fluctuations in levels of
miRNAs within the context of tumor cells in vivo. The general
expectation that changes in levels of miRNAs will be inversely
correlated (IC) with changes in levels of their mRNA targets
[10,11,12,13,14] has yet to be conclusively tested within the
context of tumor cells in vivo. For example, previous independent
estimates of relative miRNA levels in ovarian cancers vs. controls
often have been inconsistent, possibly due to differences in sample
type (e.g., bulk tissue samples vs. micro-dissected cells, etc.),
biological variability among different cancer sub-types and
individual patient samples (e.g., [15,16,17,18,19,20]) or due to
inaccuracies in the prediction of the mRNA targets [21,22].
In an effort to reduce variation that may obscure biologically
significant trends, we have conducted microarray (Affymetrix)
analyses of miRNAs and mRNAs from the same ovarian cancer
epithelial (CEPI) cells isolated from patient samples by laser
capture micro-dissection (LCM). We monitored differences in
levels of miRNA expression between CEPI and ovarian surface
epithelial (OSE) cells (collected from ovaries of normal patients)
with expression levels of their putative mRNA targets as
determined by various prediction algorithms and by experimental
validation. While ovarian cancers may arise from either the
fimbrial epithelium of the oviduct or OSE, it has recently been
shown that both classes of cells are part of a transitional epithelium
of common origin and thus either may serve as a precursor to
CEPI [23]. Since OSE can be harvested from the surface of
ovaries with minimal contamination, they were selected as
appropriate controls in our study.
We found that only ,11% of mRNA targets displaying
significant (p,0.005) changes in levels of expression in CEPI
relative to normal were IC with changes in levels of their
regulating miRNAs (p,0.01). The levels of the majority (,79%)
of target mRNAs were unchanged in CEPI while the rest (,10%)
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correlated (PC) with their respective regulating miRNAs. We
conclude that the low predictability of miRNA regulatory effects in
CEPI isolated from patient samples is attributable to the
complexity of miRNA function in vivo.
Results
The majority of miRNAs differentially expressed in CEPI
relative to OSE are up-regulated
Unsupervised hierarchical clustering of the expression profiles of
miRNAs detected on the miRChip (Asuragen Inc, Austin, TX)
was performed on three CEPI and three OSE patient samples
(Figure 1; see Table 1 for clinical information regarding samples).
The miRChip contains a total of 13,349 probes including 467
annotated human miRNAs (Sanger miRBase V9.2 [24,25,26]),
455 miRNAs annotated in various other species and 12,894
(exploratory) probes of predicted, but as yet not validated/
annotated miRNAs. Using a threshold of 2-fold or greater change,
42 miRNA probes were found to be differentially expressed
(p,0.01) between our cancer and control samples. Of these, 33
were up-regulated and 9 down-regulated in the CEPI relative to
OSE, including 12 previously annotated human miRNAs (9 up-
regulated and 3 down-regulated). A heat map of the 42
differentially expressed miRNA probes is presented in Figure 2a
(the miRNA sequences of these 42 probes, log2 difference between
CEPI and OSE, and p-values from t-test are provided in Table
S1). To independently test the validity of the differential miRNA
expression patterns determined by microarray, we conducted
measurements of miRNA levels using quantitative (real-time)
polymerase chain reaction (qPCR). Five (miR-141, miR-429, miR-
205, miR-383 and miR-320) of the 12 previously annotated human
miRNAs shown to be differentially expressed by microarray were
selected for qPCR analysis in three cancer and three control
samples. The qPCR results confirmed the differences detected in
the microarray study (Figure 2b).
In contrast to some earlier studies [15,16,18,19,20], our results
indicate that the majority of miRNAs displaying significant
differences in levels of expression between CEPI and OSE are
up-regulated in ovarian cancer. The basis of this discrepancy is
unknown but may be due to differences in sample type (e.g., bulk
tissue samples vs. micro-dissected cells, etc.) and/or biological
variability among individual patient samples. Our finding that the
majority of miRNAs are up-regulated in ovarian cancer is
consistent with the fact that miRNA targets are significantly
enriched (hypergeometric distribution, p,0.05) among mRNAs
down-regulated in our cancer samples, while up-regulated genes
have relatively few miRNA targets (Figure S1; heat maps showing
hierarchical clustering of the samples using all probesets is
presented in Figure S2 and using only differentially expressed
mRNAs in Figure S3; a list of all differentially expressed mRNAs is
presented in Table S2). A possible biological explanation of why
miRNAs are up-regulated in CEPI may lie in the fact that in
contrast to other cancers [27,28], the transition from OSE to
CEPI is postulated to involve changes from a less differentiated to
a more differentiated state [29,30,31].
Among the 12 previously annotated miRNAs displaying a
significant change in levels in the CEPI samples, miR-205, miR-
141, and miR-429 are all significantly up-regulated consistent with
previous studies linking these miRNAs with the maintenance of
cells in the differentiated epithelial state [32]. Of the miRNAs that
are down-regulated in CEPI relative to OSE, miR-320 and miR-
383 are located in regions associated with frequent DNA copy
number losses in ovarian cancer [19]. miR-320 previously has
been identified as an inhibitor of lung carcinoma proliferation
[33]. Its down-regulation in CEPI suggests that it may act as a
tumor suppressor in ovarian cancers as well.
Only ,11% of the predicted mRNA targets of miRNAs
differentially expressed between the CEPI and OSE
display the expected inverse pattern of change in gene
expression
Previous studies have established that human miRNAs repress
gene expression by pairing with complementary sequences located
within the 39 untranslated regions (39 UTR) of targeted mRNAs
resulting in translational repression and mRNA degradation [6,7].
Based on these findings, changes in the expression levels of
miRNAs are generally predicted to be inversely correlated with
changes in the expression levels of their targeted mRNAs
[10,11,12,13,14]. To test this hypothesis in the context of cells
isolated from patient samples, we compared changes in the levels
of the previously annotated human miRNAs with levels of their
predicted target mRNAs in our CEPI samples relative to the OSE
controls. The putative mRNA targets of these previously
annotated human miRNAs were initially identified using the
miRanda algorithm [34,35,36]. The results indicate that only
,11% of the changes in mRNA expression between CEPI and
OSE were inversely correlated (IC) with the observed changes in
miRNA levels (Tables 2 & S3). Earlier studies of levels of miRNAs
and their targeted mRNAs in a series of cell lines reported similar
findings [13,37,38]. The expression of the majority (No Change,
NC: ,79%) of the predicted mRNA targets was not significantly
different (p.0.005 and/or fold change ,2) between the CEPI and
OSE samples, while ,10% of the targeted mRNAs displayed
changes positively correlated (PC) with their putatively regulating
miRNAs.
To determine if the unexpectedly low percentage of IC changes
may be a computational artifact of our use of the miRanda
algorithm to predict targeted mRNAs, we repeated the analysis
independently using the PicTar (www.pictar.org) and TargetScan
(www.targetscan.org) miRNA target prediction algorithms. In
both instances, the results were consistent with our original finding
that only a minority of the changes in mRNA expression between
CEPI and OSE are inversely correlated (IC) with the observed
changes in miRNA levels (PicTar: IC 9.4%, PC 10.1%, NC
80.5%; TargetScan: IC 10.4%, PC 10.3%, NC 79.3%; see
Tables 3, S4 & S5). To increase the stringency of target
predictions, we reanalyzed the data using only miRNA targets
that were commonly predicted by all three algorithms (intersec-
tion). We found that by overlapping the three independent
prediction algorithms, each miRNA had fewer predicted targets,
yet using these commonly predicted targets, only ,7% of the
mRNA changes between CEPI and OSE were found to be
inversely correlated (IC) with the observed changes in miRNA
levels (Table 4). We also analyzed our data using intersections of
predictions from two algorithms at a time (miRanda+TargetScan,
miRanda+PicTar, and PicTar+TargetScan), and again we found
that changes in levels of only 6–9% of the predicted mRNA targets
were inversely correlated with changes in miRNA levels (Tables
S6, S7 and S8).
Experimental validation is currently considered the most
stringent method to validate miRNA targets [39,40]. Thus, to
further test the possibility that the low inverse correlation between
changes in miRNA levels and target mRNAs observed in the tissue
samples was merely a reflection of the limited accuracy of target
prediction algorithms, we conducted a series of transfection
experiments using two miRNAs that were significantly up-
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validated targets of these miRNAs in CEPI.
A series of independent transfection experiments was carried
out with miR-7, miR-128 and a matched set of negative control
miRNAs in a well-established ovarian cancer cell line (HEY) [41].
To determine the effectiveness of our transfections (positive
controls), we monitored expression levels of two previously
confirmed mRNA targets of miR-7 (epidermal growth factor
receptor, EGFR [42] and miR-128 (B lymphoma Mo-MLV
insertion region 1 homolog, BMI1 [43]) regulation. The results
confirm the effectiveness of both transfections (Figure S4). RNA
was collected from cells after transfection and the relative levels of
mRNAs present were determined by Affymetrix microarray
analyses (HG-U133 Plus 2.0; Tables S9 and S10).
Consistent with the results from CEPI tissue samples, only a
minority of predicted mRNA targets were found to be significantly
reduced (IC) after miR-7 or miR-128 transfection (Table 5). The
predicted mRNA targets that were significantly down-regulated in
these transfection experiments were taken as ‘‘experimentally
validated’’ mRNA targets of miR-7 and miR-128 respectively.
Using only these targets, we reanalyzed the microarray data from
the tissue samples and found that only ,8% (range 0–18%) of the
‘‘experimentally validated’’ mRNA targets displayed changes in
expression IC with changes in miR-7 and miR-128 expression in
Figure 1. Unsupervised hierarchical clustering of CEPI and OSE samples based on probesets expressed on the Ambion miRChip. An
unsupervised hierarchical clustering of the CEPI and OSE samples was carried out using all detected probesets on the Ambion miRChip array,
regardless of differential expression. Probesets with standard deviation ,0.5 across all samples were removed prior to clustering. The clustering
shows that the CEPI and OSE samples cluster into separate groups, which suggests the variance between the groups is greater than that within the
groups.
doi:10.1371/journal.pone.0022508.g001
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inverse correlation between changes in levels in miRNAs and their
target mRNAs in vivo is not merely an artifact of inaccurate target
predictions but rather a reflection of the complexity of miRNA
function in cancer cells.
Discussion
It is well known that genes and their mRNA products are
subject to a vast array of regulatory controls. The relative
contribution of malfunctions in these controls to the onset and
progression of diseases, such as cancer, can be varied and complex
[44]. miRNAs and other small non-coding RNAs recently have
been shown to be important regulators of gene expression, and
disruption of miRNA expression has been implicated in many
diseases including cancer [3,45,46,47,48]. While it is well
established that miRNAs can serve as useful biomarkers for the
diagnosis and staging of a variety of human cancers (e.g.,
[2,49,50]), the manner and extent to which miRNAs contribute
to the processes underlying cancer is only beginning to be
understood [2,45]. For example, the regulatory function of
miRNAs was initially believed to operate exclusively at the
translational level [51,52], but more recent findings have
demonstrated that these small regulating RNAs also play a role
in the modulation of mRNA stability and that these two modes of
control may be inter-related [7,53]. We still do not rule out the
possibility that regulation of some target genes may occur at the
translational level without significant changes in mRNA level, and
therefore may have been ignored in our analyses.
Extensive in vitro and in vivo studies previously have demonstrat-
ed that human miRNAs can repress gene expression by pairing
with sequences located within the 39 untranslated regions of
targeted messenger RNAs (mRNAs) resulting in translational
repression and subsequent mRNA degradation [1,6,7]. Thus far,
there are few examples of miRNAs increasing the transcription or
translation of target genes [54,55], resulting in positive correlations
between miRNAs and target mRNAs. Therefore, a generally held
expectation is that changes in the expression levels of mRNAs will
be inversely correlated with changes in the levels of their targeting
miRNAs [56]. However, the fact that individual miRNAs may
target multiple mRNAs and that individual mRNAs may be
targeted by multiple miRNAs creates the potential for a complex
network of interactions in cancer cells replete with a variety of
positive and negative feedback loops [57,58]. In addition, the fact
that miRNAs are well known to target mRNAs encoding a variety
of cellular transcription factors and other regulatory proteins
increases the likelihood that the direct regulatory effects of
miRNAs may be modulated by indirect or ‘‘down-stream’’ effects
within the context of cancer cells. This is not to say that the
mechanisms demonstrated to underlie miRNA regulation in vitro
are inoperative in vivo, but rather that the functional consequences
of these mechanisms may be masked and/or modulated by the
regulatory complexities that characterize cancer cells. The extent
to which these complexities may mitigate our ability to accurately
predict the molecular consequence of changes in levels of miRNAs
within the context of cancer cells has relevance to the potential use
of miRNAs in cancer therapy.
The purpose of our study was to evaluate the extent to which the
molecular consequences of changes in miRNA levels in cancer cells
isolatedfrom patienttissues canbepredictedfromcurrentmodels of
miRNA function. The fact that prior efforts to obtain expression
profiles of miRNAs and their mRNA targets were typically carried
out on samples obtained from different patients and/or from mixed
(bulk) tissues have contributed to inconsistent findings (e.g.,
[15,16,17,18,19,20]). In an effort to reduce experimental variation,
we assayed changes in levels of miRNAs and their targeted mRNAs
in ovarian cancer cells isolated from the same patients by LCM.
Our results indicate that only ,11% of the changes in levels of
mRNAs are IC with changes in levels of their regulating miRNAs in
the same ovarian cancer (CEPI) cells. To eliminate the possibility
that our results are merely an artifact of incorrectly identified
mRNA targets of miRNA regulation, we repeated our analyses
using targets predicted by a variety of prediction algorithms, as well
as, targets experimentally validated in a series of transfection
experiments conducted in a well-documented ovarian cancer cell
line (HEY). Our results consistently support the conclusion that the
expected IC between changes in miRNA levels and levels of their
target mRNAs occurs relatively infrequently in ovarian cancer cells
isolated from patient samples and that this low inverse correlation is
not merely an artifact of inaccurate miRNA target predictions.
Rather, our results indicate that the low inverse correlation between
changes in miRNA levels and levels of their target mRNAs is the
likely consequence of indirect cellular processes that modulate or
mask the regulatory effects of miRNAs in vivo. Our findings
underscore the complexities of miRNA-mediated regulation in vivo
andthe need forbetterunderstandingthebasis ofthesecomplexities
in cancer cells before the therapeutic potential of miRNAs can be
fully realized.
Materials and Methods
Tissue samples
Ovarian tumor samples were collected at Northside Hospital
(Atlanta, GA) during surgery and snap frozen in liquid nitrogen
within 1 minute of removal from patients. All ovarian tumor
Table 1. Clinical information of patient samples used in this
study.
Patient
ID Ovarian Histopathology Stage/Grade
Age at Surgery
(years)
551
a,b,c papillary serous carcinoma IIIc/IV/3 59
588
a,b,c papillary serous carcinoma IIIc/2-3 71
489
a,b papillary serous carcinoma IV/3 48
620
c papillary serous carcinoma III/IV/3 62
434
a within normal limits N/A 41
440
a within normal limits N/A 50
475
a within normal limits N/A 63
470
a Ov-within normal limits;
hx of endometrial ca.
Ov-N/A
Endo-1b/1
44
437
a Ov-within normal limits;
hx of cervical ca.
Ov-N/A
Cerv-1b/3
54
482
b within normal limits N/A 44
665
b within normal limits N/A 84
783
b,c within normal limits N/A 52
838
c within normal limits N/A 51
846
c within normal limits N/A 51
amRNA microarray;
bmicroRNA microarray;
creal-time PCR.
Clinical information relevant to this study for each patient is shown. In addition,
a legend is given to identify which patient was used for each microarray and
qPCR experiment. Abbreviations used- Cerv: Cervix; Endo: Endometrium; Ov:
Ovary; ca.: Carcinoma; hx: History.
doi:10.1371/journal.pone.0022508.t001
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serous papillary epithelial ovarian carcinoma. Brushings of normal
ovarian surface epithelial cells (OSE) were preserved immediately
in RNAlater (Ambion, Austin, TX). Patient consent and approval
from the Institutional Review Boards of Georgia Institute of
Technology and Northside Hospital were obtained. The written
consent and our protocol (#H09227) were approved by the IRB.
Detailed clinical information for each patient used in this study is
provided in Table 1.
Laser capture micro-dissection (LCM)
Fresh frozen tissues from tumors were cut into seven-micron
sections, applied to non-charged slides, then fixed in 75% ethanol
for 30 seconds, stained and dehydrated using the HistoGene LCM
Frozen Section Staining Kit (Arcturus, Mountain View, CA).
LCM was performed with an AutoPix Automated Laser Capture
Microdissection System using the CapSure Macro Caps (Arctu-
rus). Approximately 10,000 cells were captured on each of 5–6
caps per sample. miRNA was extracted from captured cells using
the mirVana miRNA Isolation Kit (Ambion). mRNA was isolated
from cells from the same patients using the PicoPure RNA
Isolation Kit (Arcturus).
RNA extraction from ovarian surface epithelial cells
For miRNA qPCR and microarray, normal ovarian surface
epithelial cells were spun down and resuspended in lysis buffer
from the mirVana miRNA Isolation Kit (for small RNA
enrichment), following the manufacturer’s recommended protocol
(Ambion). cDNA for qPCR was synthesized from RNA (10ng)
using the TaqMan miRNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA).
For mRNA qPCR and microarray total RNA extraction from
OSE was carried out using the PicoPure RNA Isolation Kit,
following the manufacturer’s recommended protocol (Arcturus).
Due to limited number of cells collected from surface epithelial
brushings, OSE RNA was extracted from 5 patients with non-
malignant ovaries for mRNA microarray and from two different sets
of three patients with non-malignant ovaries for miRNA (one set
for miRNA microarray, another for qPCR) (See Table 1 for more
details on patient information).
Quantitative (real-time) PCR
Total RNA (10ng) extracted from LCM captured ovarian tumor
cells and normal OSE cells was converted to amplified cDNA for
qPCR. TaqMan miRNA Assays (Applied Biosystems) were
conducted following manufacturer’s protocol for hsa-miR-141,
hsa-miR-429, hsa-miR-205, hsa-miR-320, hsa-miR-383 and for
RNU6B endogenous control using the StepOnePlus Real-Time
PCR machine (Applied Biosystems). The primer specificities for
these miRNAs have been previously demonstrated [58–63] and
Table 2. Summary values of IC, PC and NC targets in CEPI vs.
OSE using miRanda.
miRNA
Total Targets
(miRanda)
Inversely
Correlated
Targets (%)
No
Change
(%)
Positively
Correlated
Targets (%)
miR-7 2363 10.62 79.94 9.44
miR-18a 1738 11.10 79.86 9.03
miR-18b 1710 11.40 79.24 9.36
miR-126 84 14.29 75.00 10.71
miR-128 2691 11.82 79.23 8.96
miR-141 3074 13.53 77.91 8.56
miR-205 2268 13.49 78.31 8.20
miR-429 3316 13.48 78.62 7.90
miR-93* 2252.00 13.14 77.00 9.86
Average (for up-
regulated miRNAs)
2166.22 12.54 78.34 9.11
miR-383 2118 9.02 78.80 12.18
miR-320a 3073 8.30 79.08 12.63
miR-193a-5p 1216 12.01 78.45 9.54
Average (for down-
regulated miRNAs)
2135.67 9.77 78.78 11.45
Average (for
Up and Down)
2150.94 11.16 78.56 10.28
miRNA targets that were differentially expressed between CEPI and OSE based
on t-test p,0.005 and fold change of at least 2 were classified as being IC or PC
with their regulating miRNAs (while target genes that do not meet the above
criteria are classified as NC). Total number of targets from miRanda algorithm
present after removing probe sets with ‘‘Absent’’ calls in all samples is shown
along with fraction of IC, PC and NC targets for each miRNA. On average, 78.6%
of the target mRNAs are ‘‘No Change’’, or do not change significantly with
miRNAs, 11.2% are ‘‘inversely correlated’’ and 10.3% are ‘‘positively correlated’’
with miRNAs.
doi:10.1371/journal.pone.0022508.t002
Figure 2. Differentially expressed miRNAs in CEPI cells from ovarian cancer patients relative to OSE. (A) Hierarchical clustering of
normal and cancer patient samples based on differentially expressed miRNAs between CEPI cells and OSE cells (p,0.01, $2fold change). The
dendogram on the left shows that the probes cluster into two groups corresponding to the up-regulated and down-regulated miRNAs differentially
expressed between normal and cancer. IDs of selected probes are given on the right (including the annotated human miRNAs, see Table S1 for a
complete list). Key: hsa-miR-x: annotated human miRNAs; hsa-asg/cand-x: predicted candidate human miRNAs; ppy-: Pongo pygmaeus miRNA; cel-: C.
elegans miRNA. (B) Confirmation of expression patterns for selected miRNAs by qPCR. The relative expression of each miRNA in logarithmic units in
cells from 3 cancer patients is shown compared to cells from 3 normal ovaries after normalization to RNU6B (DDCt method). These were found to be
statistically significant by Relative Expression Software Tool (RESTH) by a randomization method. Randomization was performed 5000 times.
Consistent with the microarray results, miR-141, miR-205 and miR-429 were confirmed to be significantly up-regulated in cancer, while miR-320 and
miR-383 were found to be significantly down-regulated. Error bars represent standard error of the mean.
doi:10.1371/journal.pone.0022508.g002
Table 3. Summary of average IC, PC and NC fractions based
on miRanda, PicTar and TargetScan predicted targets.
Inversely
Correlated
Targets (%) No Change (%)
Positively
Correlated
Targets (%)
miRanda 11.16 78.56 10.28
TargetScan (TS) 10.37 79.34 10.29
PicTar (PT) 9.41 80.48 10.11
Average of different
algorithms
10.31 79.46 10.23
Average fraction of IC, NC and PC targets in CEPI vs. OSE calculated for all 12
annotated miRNAs using miRanda, TargetScan (TS) or PicTar (PT) (See Tables 2,
S4 and S5 for details). The average IC, NC and PC fractions of the mean values
calculated from these 3 different algorithms are also shown.
doi:10.1371/journal.pone.0022508.t003
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(http://www.ambion.com/techlib/tn/151/3.html; http://www3.
appliedbiosystems.com/cms/groups/mcb_marketing/documents/
generaldocuments/cms_044972.pdf). Statistical significance was
determined using the Relative Expression Software Tool (REST;
[59]).
For mRNA qPCR, total RNA (1–5 mg) extracted from cells was
converted to cDNA using the Superscript III First Strand synthesis
system (Invitrogen). cDNA was then purified using the QIAGEN
PCR purification kit (QIAGEN) following manufacturer’s instruc-
tions. qPCR experiments were carried out for the EGFR, BMI1
and GAPDH genes using iQ SYBR Green Supermix (Bio-Rad,
Hercules, CA). The sequence specific primers used for SYBR
green assays are as follows: EGFR-forward: GGAGAACTGC-
CAGAAACTGACC, EGFR-reverse: GCCTGCAGCACACTG-
GTTG, GAPDH-forward: GGTCTCCTCTGACTTCAACA,
GAPDH-reverse: AGCCAAATTCGTTGTCATAC, BMI1-for-
ward: ACTTCATTGATGCCACAACC, BMI1-reverse: CA-
GAAGGATGAGCTGCATAA. The EGFR primers were as
designed by [60] and GAPDH primers were as designed by
[61]. BMI1 primers were obtained from the qPCR primer
database RTPrimerDB [62]. The GAPDH primer efficiencies
were calculated to be ,1. The specificity of the other primers can
be obtained from the relevant publications/database. All qPCR
reactions (for mRNA and miRNA) were optimized with non-
template controls and -RT (minus reverse transcriptase) controls
prior to experiment. GAPDH was chosen as endogenous control
as it displayed minimal change between cells transfected with miR-
NC and miR-7/128 in microarray.
All qPCR reactions were carried out with at least 2 biological
replicates and for each biological replicate at least 3 technical
replicates.
Cell culture and Cell Transfections
HEY cells were provided by Gordon B. Mills, Department of
Systems Biology, the University of Texas, M. D. Anderson Cancer
Center. The cells were cultured in RPMI 1640 (Mediatech,
Manassas, VA) supplemented with 10% v/v heat-inactivated fetal
calf serum (Invitrogen, Carlsbad, CA), 2 mM L-glutamine
(Mediatech), 10 mM HEPES buffer (Mediatech), penicillin
(100 U/ml), and streptomycin (100 mg/mL). Approximately 12h
before transfection, these cells (duplicates or triplicates per
transfection, 1.5610
5 per well) were seeded on six-well plates in
growth medium and allowed to adhere overnight at 37uCi na5 %
CO2 atmosphere. The following day after washing the wells with
PBS and replacing the growth medium with Opti-MEM
(Invitrogen), cells were transfected with the miRNA [hsa-miR-7
miRIDIAN mimic, miRIDIAN miRNA mimic negative control
#1 (miR-NC, a C. elegans miRNA, cel-miR-67, with confirmed
minimal sequence identity in humans), or hsa-miR-128 miRI-
DIAN mimic (Thermo Fisher Scientific, Lafayette, CO)] using
Lipofectamine 2000 transfection agent (Invitrogen) according to
Table 4. Summary values of IC, PC and NC targets in CEPI vs.
OSE using overlap of miRanda, TargetScan and PicTar target
predictions.
miRNA
Total Targets
(M_TS_PT)
Inversely
Correlated
Targets (%)
No Change
(%)
Positively
Correlated
Targets (%)
miR-7 105 10.48 84.76 4.76
miR-18a 59 13.56 83.05 3.39
miR-18b 59 13.56 83.05 3.39
miR-126 2 0.00 100.00 0.00
miR-128 237 11.81 79.75 8.44
miR-141 177 15.82 74.58 9.60
miR-205 73 21.92 67.12 10.96
Average (for
up-regulated
miRNAs)
101.71 12.45 81.76 5.79
miR-383 15 0.00 80.00 20.00
miR-320a 112 3.57 84.82 11.61
miR-193a-5p 2 0.00 50.00 50.00
Average (for
down-regulated
miRNAs)
43.00 1.19 71.61 27.20
Average (for
Up and Down)
72.36 6.82 76.68 16.50
miRNA targets that were differentially expressed between CEPI and OSE based
on t-test p,0.005 and fold change of at least 2 were classified as being IC or PC
with their regulating miRNAs (while target genes that do not meet the above
criteria are classified as NC). Total number of targets from the intersection
(M_TS_PT) of miRanda (M), TargetScan (TS) and PicTar (PT) predictions present
after removing probe sets with ‘‘Absent’’ calls in all samples is shown along with
fraction of IC, PC and NC targets for each miRNA. On average, 76.7% of the
target mRNAs are ‘‘No Change’’, or do not change significantly with miRNAs,
6.8% are ‘‘inversely correlated’’ and 16.5% are ‘‘positively correlated’’ with
miRNAs.
doi:10.1371/journal.pone.0022508.t004
Table 5. Summary values of IC, PC and NC targets in
transfection experiments using miRanda, TargetScan and
PicTar target predictions.
miRNA_prediction
algorithm
Total
Targets
Inversely
Correlated
Targets (%)
No Change
(%)
Positively
Correlated
Targets (%)
miR-7 transfection
miR-7_M 2432 7.98 91.24 0.78
miR-7_TS 259 23.55 75.29 1.16
miR-7_PT 238 16.39 83.19 0.42
miR-7_M_TS 234 20.51 78.63 0.85
miR-7_PT_TS 118 22.88 77.12 0
miR-7_M_PT 159 20.75 79.24 0
miR-7_M_TS_PT 99 23.23 76.77 0
miR-128 transfection
miR-128_M 2744 9.55 79.15 11.30
miR-128_TS 654 16.36 73.85 9.79
miR-128_PT 441 15.19 74.60 10.20
miR-128_M_TS 449 20.04 72.83 7.13
miR-128_TS_PT 301 16.94 73.75 9.30
miR-128_M_PT 306 17.32 74.18 8.50
miR-128_TS_M_PT 221 19.91 73.30 6.79
miRNA targets that were differentially expressed between miR-7 or miR-128
transfected cells compared to negative control miRNA transfected cells, based
on fold change of at least 1.4 and false discovery rate threshold of 5% were
classified as being IC or PC with their regulating miRNAs (while target genes
that do not meet the above criteria are classified as NC). Total number of targets
from miRanda (M), TargetScan (TS) and PicTar (PT) or their intersections (two at
time and all three) present after removing probe sets with ‘‘Absent’’ calls in all
samples is shown along with fraction of IC, PC and NC targets for each miRNA.
doi:10.1371/journal.pone.0022508.t005
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Cells were incubated for four hours in this reduced serum
environment to optimize transfection, washed with PBS, and then
incubated at 37uC and 5% CO2 for 44 h (total 48 h) after adding
fresh growth medium to the wells. Transfection efficiency was
estimated from the relative knock-down of previously validated
targets (EGFR for miR-7 and BMI-1 for miR-128 [42,43]), based
on recommendations by the siRNA/miRNA reagent manufac-
turer (Thermo Fisher Scientific). Cell culture experiments were
carried out using at least two-three independent biological
replicates.
Microarray
Tissue mRNA microarray. Biotin labeled cRNA was
synthesized, hybridized to Affymetrix HG-U133 Plus 2.0
oligonucleotide arrays and analyzed with a GeneChip Scanner
3000 (Affymetrix, Santa Clara, CA).
HEY cell RNA isolation and mRNA microarray. Total
RNA was isolated using the RNeasy Mini RNA isolation kit
(QIAGEN, Valencia, CA) according to the manufacturer’s
instructions. The integrity of the RNA was verified using an
Agilent 2100 Bioanalyzer (1.8–2.0; Agilent Technologies, Palo
Alto, CA). mRNAs were converted to double stranded (ds)-cDNA
and amplified using Applause 39-Amp System (NuGen, San
Carlos, CA). This cDNA was then biotin labeled and fragmented
by using Encode Biotin Module (NuGen). The labeled cDNA was
hybridized to Affymetrix HG-U133 Plus 2.0 oligonucleotide arrays
and analyzed with a GeneChip Scanner 3000 (Affymetrix).
Microarray data analysis
Tissue miRNA microarray data analysis. Samples for our
miRNA profiling study were processed by Asuragen Services
(Austin, TX), according to the company’s standard operating
procedures. A custom-manufactured Affymetrix GeneChipH from
Ambion was designed to miRNA probes derived from the Sanger
miRBase and published reports [24,25,26,63,64,65]. Background
signal was estimated from antigenomic probe sequences provided
by Affymetrix and derived from a larger set of controls used on the
Affymetrix human exon array. Spike-in external reference controls
were based on non-miRNA control probes that lack homology to
the human genome. Arrays within a specific analysis experiment
were normalized according to the variance stabilization method
described in [66]. A Wilcoxon rank-sum test was used to
determine detection calls of the miRNA probe signal compared
to the distribution of signals from GC-content matched anti-
genomic probes.
A two-sample t-test, with assumption of equal variance, was
applied for statistical hypothesis testing. This test defined which
probes are considered to be significantly differentially expressed
based on a p-value of 0.01 and log2 difference $1. The signal
intensities from these differentially expressed probes were z-score
normalized prior to hierarchical clustering.
Unsupervised hierarchical clustering of the samples was
performed using Spotfire Decisionsite for Microarray Analysis
(DSMA) based on Z-score transformed signal values of all
probesets except those with standard deviation ,0.5. A ‘‘complete
linkage’’ clustering method was employed with ‘‘correlation’’
‘similarity measure’. Empty values were replaced with the constant
0.
Tissue mRNA microarray data analysis. CEL files
generated by the Affymetrix Gene Chip Operating System
(GCOS) were converted to expression level values using the
MAS 5.0 package implemented using the Affymetrix Expression
Console software. The log2 transformed expression values were
then normalized across samples by Z-score calculations using
DSMA. Probe sets with ‘‘Absent’’ call in all groups were removed
from further statistical analysis. Probe set intensities were filtered
with DSMA using a modulation threshold of 1.0 to include only
those probe sets with at least a log2 expression value of $1.0 or
fold change $2. Differentially expressed probe sets were identified
using the t-test function of the Profile ANOVA Tool of DSMA
(p,0.005). Annotations for probe sets were obtained from
the NetAffx website (http://www.affymetrix.com/analysis/index.
affx).
Unsupervised hierarchical clustering of the samples was
performed using DSMA based on Z-score transformed signal
values of all probesets except those with standard deviation ,0.5
and ‘‘Absent’’ call across all samples. A ‘‘complete linkage’’
clustering method was employed with ‘‘correlation’’ ‘similarity
measure’. Empty values were replaced with the constant 0.
HEY cell mRNA microarray data analysis. Raw data in
the form of CEL files were produced by Affymetrix GeneChip
Operating System (GCOS) software. Raw data from mRNA
microarray were analyzed using the Expression Console software
(Affymetrix) and R (www.r-project.org). Normalization was
performed using MAS 5.0, PLIER (Expression Console) and
GCRMA (R) algorithms. The log2 transformed expression values
from MAS5.0 were then analyzed for Affymetrix ‘‘Present/
Absent’’ calls using DSMA. Probe sets with ‘‘Absent’’ call in all
groups were removed from statistical analysis. Average probe set
Table 6. Summary values of IC, PC and NC mRNAs in CEPI vs.
OSE for miR-7 and miR-128 using ‘‘experimentally validated’’
targets only.
miRNA_prediction
algorithm
Total
Targets
Inversely
Correlated
Targets (%)
No Change
(%)
Positively
Correlated
Targets (%)
miR-7_M 180 12.22 80.56 7.22
miR-7_TS 60 6.67 88.33 5
miR-7_PT 37 0 91.89 8.11
miR-7_M_TS 47 6.38 87.23 6.38
miR-7_PT_TS 27 0 96.30 3.70
miR-7_PT_M 33 0 90.91 9.09
miR-7_M_TS_PT 23 0 95.65 4.35
Average for miR-7
(all methods)
58.14 3.61 90.12 6.26
miR-128_M 252 11.90 74.60 13.49
miR-128_TS 103 10.68 75.73 13.59
miR128_PT 63 17.46 69.84 12.70
miR-128_M_TS 87 12.64 72.41 14.94
miR-128_PT_TS 49 16.33 69.39 14.29
miR-128_M_PT 52 11.54 75 13.46
miR-128_M_PT_TS 43 11.63 72.09 16.28
Average for miR-128
(all methods)
92.71 13.17 72.73 14.11
Average (overall) 75.43 8.39 81.42 10.19
Targets that were predicted by miRanda (M), TargetScan (TS), PicTar (PT) or any
combination of the 3 programs and were down-regulated (FDR,5%, fold
change$2|1.4|) in miR-7 transfection or in miR-128 transfection were assumed
to be experimentally validated targets. The direction of change of these same
targets in CEPI vs. OSE were then used to calculate IC, NC and PC fractions using
a p-value,0.005 and a fold change of at least 2 in the tissue microarray data.
doi:10.1371/journal.pone.0022508.t006
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transformed values from PLIER and then filtered with DSMA
using a modulation threshold of 0.5 to include only those probe
sets with at least a fold change $1.4 [log2 difference $0.5]. The
false discovery rate (FDR) for each probe set was calculated from
the log2 transformed values after GCRMA normalization using
the SAM algorithm [67]. Finally, differentially expressed probe
sets were identified using a threshold 5% FDR correction, a fold
change $1.4 and at least ‘‘Present/Marginal’’ call in one sample.
These 3 different filtering approaches were used based on
recommendations from recent publication by Mieczkowski et al.
[68] and the combination of all three was used to achieve the most
stringent filtering.
All microarray data from this study are MIAME compliant and
have been submitted to GEO under the accession no. GSE23392.
miRNA target download
The miRNA targets prediction file based on miRanda was
downloaded from www.microrna.org (August 2010 release)
[34,35,36]. Information about the prediction algorithm, parameter
settings and raw data source is available on the above link. Only
predicted targets with ‘‘good’’ mirSVR score were used. ‘‘Good’’
mirSVR score refers to miRNA targets with ,20.1 score, and
‘‘non-good’’ mirSVR score refers to targets with .20.1 score
obtained from the support vector regression algorithm mirSVR,
available with target predictions in the above link. The miRNA
targets prediction file based on TargetScan (release 5.1) was
downloaded from www.targetscan.org [69,70,71]. Targets based on
PicTar [72,73,74,75] prediction were also bulk downloaded from
the UCSC database. miRNAs for which PicTar predictions were
not present in the bulk data file, were manually curated from the
tables available on the PicTar web interface (www.pictar.org).
Predicted target sites analysis
Target sites for 12 differentially expressed miRNAs were
selected from the downloaded target prediction files or from the
web interface (PicTar). Of those, target sites with Affymetrix
‘‘Absent’’ call in every sample were excluded from further analysis.
Each target mRNA was classified as IC, NC or PC depending on
the direction of its change in level of expression between OSE and
CEPI and that of each targeting miRNA.
Predicted targets of the miRNAs miR-7 and miR-128 identified
by miRanda, TargetScan, PicTar and all combinations of the 3
programs were used to calculated IC, NC, and PC fraction of
targets in HEY cells transfected by each miRNA (miR-7 or miR-
128) based on significance at a fold change threshold of 1.4 and
maximum FDR of 5%. Predicted targets that were down-
regulated in the transfection experiments were assumed to be
‘‘experimentally validated’’ and the expression patterns of these
experimentally validated targets were subsequently used in
comparisons between the CEPI and OSE samples (as described
above) to identify IC, PC and NC fractions based on significance
at a fold change threshold of 2 and t-test p-value ,0.005.
Supporting Information
Figure S1 Overlap between differentially expressed
genes in ovarian cancer and miRNA target genes.
Genomica was used to calculate significant (false discovery rate
corrected q,0.05) gene set overlaps between genes differentially
expressed in the ovarian cancer data set and gene sets containing
targets of individual miRNAs. This is analogous to a ‘‘GO’’ (gene
ontology) enrichment analysis (the miRNA identities are the
‘‘ontologies’’ in this case). The coloring represents the percentage
(%) of genes within the cancer data set that overlap with the
individual miRNA target gene set listed on the right. The miRNAs
listed here include differentially expressed miRNAs found in our
microarray experiment as well as additional miRNAs predicted
using Genomica.
(TIF)
Figure S2 Unsupervised hierarchical clustering of CEPI
and OSE samples based on probesets expressed on the
HG-U133 Plus 2.0 array. An unsupervised hierarchical
clustering of the 5 CEPI and 3 OSE samples was carried out
using all detected probesets on the HG-U133 Plus 2.0 array,
regardless of differential expression. Probesets with standard
deviation ,0.5 and ‘‘Absent’’ calls across all samples were
removed prior to clustering. The clustering shows that the CEPI
and OSE samples cluster into separate groups, which suggests the
variance between the groups is greater than that within the groups.
(TIF)
Figure S3 Differentially expressed mRNAs between
CEPI and OSE. Hierarchical clustering of differentially expressed
genes between CEPI samples and OSE samples. The ,3650
probesets correspond to ,2700 unique gene symbols and were
selected based on p-value ,0.005, fold change $2, and Affymetrix
‘‘Present/Marginal’’ call in at least one sample. The dendogram on
the left clusters the up-regulated genes and down-regulated genes into
two groups and the number of genes in each of these classes are
approximately equal. Gene symbols corresponding to representative
differentially expressed probesets are shown on the right (See Table
S2 for listing of all differentially expressed probesets).
(TIF)
Figure S4 Confirmation of successful miR-7 and miR-
128 transfection into HEY cells. Successful transfection of
miR-7 and miR-128 in HEY cells (positive control) was confirmed
by measuring levels of two previously demonstrated targets of
these miRNAs, EGFR and BMI1, by qPCR following transfection
of either miR-NC or miR7/miR-128 into HEY cells. The results
demonstrate that both BMI1 and EGFR were down-regulated by
,60% relative to miR-NC (*** p,0.005) after transfection with
miR-128 and miR-7 respectively.
(TIF)
Table S1 Differentially expressed miRNA probesets
detected by microarray. Forty-two differentially expressed
miRNA probesets in 3 CEPI and 3 OSE samples as analyzed by
microarray (Ambion miRChip V1). These probesets were selected
based on a p-value ,0.01, log2 difference $1, and Affymetrix
‘‘Present/Marginal’’ call in at least 1 sample. The mature miRNA
names and the sequences corresponding to each probeset, the
average log expression values from the OSE and CEPI samples, as
well as, the log2 difference and t-test p-value calculated from these
are given. Probesets that do not refer to miRNAs currently
annotated in Sanger miRBase are listed as ‘‘exploratory’’.
Sequences of these exploratory miRNAs are based on computa-
tional predictions from previous studies.
(XLS)
Table S2 Differentially expressed mRNA probes in
CEPI compared to OSE. Differentially expressed mRNA
probesets between 3 CEPI samples and OSE from 5 normal
samples as analyzed by microarray (Affymetrix HG-U133 Plus
2.0). These probesets were selected based on a p-value ,0.005,
fold change $2, and Affymetrix ‘‘Present/Marginal’’ call in at
least one sample. The gene symbols corresponding to each
probeset ID, the average log expression values from the OSE and
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calculated from these are given.
(XLS)
Table S3 IC, PC and NC targets of miRNAs in tissue
samples. Target predictions from miRanda (M), TargetScan
(TS) and PicTar (PT) programs were downloaded (see methods for
details) for each of the 12 annotated miRNAs. miRNA targets that
were differentially expressed between CEPI and OSE based on t-
test p,0.005 and fold change of at least 2 were classified as being
IC or PC with their regulating miRNAs (while target genes that do
not meet the above criteria are classified as NC). The IC targets
are shown in green, PC targets are shown in red, and blue
represents NC targets. Targets with ‘‘Absent’’ calls in all samples
have been removed. For miR-93*, TargetScan custom (TScustom)
(http://www.targetscan.org/vert_50/seedmatch.html) was used to
generate TargetScan predictions. For hsa-miR-429 and hsa-miR-
93* there were no PicTar predictions and thus targets of these
miRNAs were excluded for analysis when calculating intersections.
(XLS)
Table S4 Summary values of IC, PC and NC targets
using TargetScan. miRNA targets that were differentially
expressed between CEPI and OSE based on t-test p,0.005 and
fold change of at least 2 were classified as being IC or PC with
their regulating miRNAs (while target genes that do not meet the
above criteria are classified as NC). Total number of targets from
TargetScan algorithm present after removing probesets with
‘‘Absent’’ calls in all samples is shown along with fraction of IC,
PC and NC targets for each of the 12 annotated miRNAs. On
average, 79.3% of the target mRNAs are NC, 10.4% are inversely
correlated and 10.3% are positively correlated with miRNAs.
(XLS)
Table S5 Summary values of IC, PC and NC targets
using PicTar. miRNA targets that were differentially expressed
between CEPI and OSE based on t-test p,0.005 and fold change of at
least 2 were classified as being IC or PC with their regulating miRNAs
(while target genes that do not meet the above criteria are classified as
NC). Total number of targets from PicTar algorithm present after
removing probesets with ‘‘Absent’’ calls in all samples is shown along
with fraction of IC, PC and NC targets for each of the 12 annotated
miRNAs. On average, 80.5% of the target mRNAs are in the NC
group, 9.4% are in the IC group and 10.1% are in the PC group.
(XLS)
Table S6 Summary values of IC, PC and NC targets
using overlap of miRanda and TargetScan predictions.
miRNA targets that were differentially expressed between CEPI
and OSE based on t-test p,0.005 and fold change of at least 2
were classified as being IC or PC with their regulating miRNAs
(while target genes that do not meet the above criteria are classified
as NC). Total number of targets from the overlap of miRanda (M)
and TargetScan (TS) algorithms present after removing probesets
with ‘‘Absent’’ calls in all samples is shown along with fraction of
IC, PC and NC targets for each of the 12 annotated miRNAs. On
average, 79.2% of the target mRNAs are in the NC group, 9% are
in the IC group and 11.8% are in the PC group.
(XLS)
Table S7 Summary values of IC, PC and NC targets
using overlap of miRanda and PicTar predictions.
miRNA targets that were differentially expressed between CEPI
and OSE based on t-test p,0.005 and fold change of at least 2
were classified as being IC or PC with their regulating miRNAs
(while target genes that do not meet the above criteria are classified
as NC). Total number of targets from the overlap of miRanda (M)
and PicTar (PT) algorithms present after removing probesets with
‘‘Absent’’ calls in all samples is shown along with fraction of IC,
PC and NC targets for each of the 12 annotated miRNAs. On
average, 78.3% of the target mRNAs are in the NC group, 8.6%
are in the IC group and 13.1% are in the PC group.
(XLS)
Table S8 Summary values of IC, PC and NC targets
using overlap of TargetScan and PicTar predictions.
miRNA targets that were differentially expressed between CEPI
and OSE based on t-test p,0.005 and fold change of at least 2
were classified as being IC or PC with their regulating miRNAs
(while target genes that do not meet the above criteria are
classified as NC). Total number of targets from the overlap of
TargetScan (TS) and PicTar (PT) algorithms present after
removing probesets with ‘‘Absent’’ calls in all samples is shown
along with fraction of IC, PC and NC targets for each of the 12
annotated miRNAs. On average, 76.8% of the target mRNAs are
in the NC group, 6.4% are in the IC group and 16.7% are in the
PC group.
(XLS)
Table S9 Differentially expressed genes between miR-7
transfected and negative control transfected HEY cells.
Differentially expressed genes (fold change $1.4, 5% FDR) in
miR-7 transfected cells compared to miR-NC transfected cells.
‘Probeset ID’ refers to Affymetrix HG-U133 Plus 2.0 probeset
identifier. ‘Gene Symbol’ shows the official gene symbol for the
corresponding Probeset ID. ‘log difference (miR7-miR-NC)’ refers
to the difference between average log2 signal values of miR-7
transfected group and the miR-NC transfected group. ‘q-value
(%)’ shows the false discovery rate calculated using the SAM
algorithm. Targets of miR-7 predicted by miRanda (M),
TargetScan (TS), and PicTar (PT) programs are also shown.
(XLS)
Table S10 Differentially expressed genes between miR-
128 transfected and negative control transfected HEY
cells. Differentially expressed genes (fold change $1.4, 5% FDR)
in miR-128 transfected cells compared to miR-NC transfected
cells. ‘Probeset ID’ refers to Affymetrix HG-U133 Plus 2.0
probeset identifier. ‘Gene Symbol’ shows the official gene symbol
for the corresponding Probeset ID. ‘log difference (miR128-miR-
NC)’ refers to the difference between average log2 signal values of
miR-128 transfected group and the miR-NC transfected group. ‘q-
value (%)’ shows the false discovery rate calculated using the SAM
algorithm. Predicted targets from miRanda (M), TargetScan (TS),
and PicTar (PT) are also shown.
(XLS)
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